SONOSCAPE(SZ:300633)2023-09-27 08:26Group 1: Company Overview - The participating units include Abu Dhabi Investment Authority, Hongtu Innovation Fund, Invesco Great Wall, Baoying Fund, and Guoyuan Securities [1] - The company is Shenzhen Kaili Biomedical Technology Co., Ltd. [4] Group 2: Investor Relations Activities - The investor relations activities took place from September 25 to 27, 2023, in the company meeting room [3] - The activities included analyst meetings, media interviews, performance briefings, press releases, roadshows, site visits, one-on-one communications, and conference calls [2] Group 3: Product Performance and Market Position - The HD-550 series has seen significant growth in sales revenue, with an increased number of multi-scope working machines in clinical settings [3] - The company has adjusted its internal sales assessment mechanism to enhance the importance of installation data in sales personnel performance [3] - The market share of the company's digestive endoscopes has surpassed some imported brands, with products recognized in over 300 tertiary hospitals in China [5] Group 4: Product Development and Upgrades - The new HD-580 series represents a significant upgrade over the HD-550, featuring improved image quality, contrast, signal-to-noise ratio, and electronic staining algorithms [5] - The company aims to continuously invest a high percentage of its revenue in R&D to address gaps in product lifespan and high-end functionalities compared to imported brands [5]